Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Brett Hagen Biography and Net Worth

CAO of AlloVir

Brett R. Hagen is the Chief Accounting Officer at AlloVir.

What is Brett R. Hagen's net worth?: The estimated net worth of Brett R. Hagen is at least $27,676.42 as of November 19th, 2024. Mr. Hagen owns 68,506 shares of AlloVir stock worth more than $27,676 as of December 20th. This net worth approximation does not reflect any other assets that Mr. Hagen may own. Learn More about Brett R. Hagen's net worth.
How old is Brett R. Hagen?: Mr. Hagen is currently 51 years old. There are 7 older executives and no younger executives at AlloVir. The oldest executive at AlloVir is Mr. Vikas Sinha C.A., CPA, M.B.A., President, CFO & Director, who is 61 years old. Learn More on Brett R. Hagen's age.
How do I contact Brett R. Hagen?: The corporate mailing address for Mr. Hagen and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Brett R. Hagen's contact information.
Has Brett R. Hagen been buying or selling shares of AlloVir?: Within the last three months, Brett R. Hagen has sold $922.13 of AlloVir stock. Most recently, Brett R. Hagen sold 554 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $0.55, for a transaction totalling $304.70. Following the completion of the sale, the chief accounting officer now directly owns 68,506 shares of the company's stock, valued at $37,678.30. Learn More on Brett R. Hagen's trading history.
Who are AlloVir's active insiders?: AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.
Are insiders buying or selling shares of AlloVir?: In the last year, insiders at the sold shares 53 times. They sold a total of 211,951 shares worth more than $149,284.16. The most recent insider tranaction occured on November, 19th when CAO Brett R Hagen sold 554 shares worth more than $304.70. Insiders at AlloVir own 32.1% of the company. Learn More about insider trades at AlloVir.
Information on this page was last updated on 11/19/2024.

Brett R. Hagen Insider Trading History at AlloVir

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Sell	554	$0.55	$304.70	68,506
10/21/2024	Sell	479	$0.78	$373.62	71,201
10/3/2024	Sell	301	$0.81	$243.81	71,680
8/5/2024	Sell	1,692	$0.73	$1,235.16	72,525
7/22/2024	Sell	481	$0.74	$355.94	74,217
7/19/2024	Sell	479	$0.75	$359.25	74,698
5/3/2024	Sell	1,597	$0.80	$1,277.60	76,022
4/22/2024	Sell	480	$0.75	$360.00	77,619
4/19/2024	Sell	473	$0.75	$354.75	78,099
4/2/2024	Sell	281	$0.77	$216.37	78,572
2/8/2024	Sell	11,150	$0.67	$7,470.50	79,347
2/5/2024	Sell	5,792	$0.67	$3,880.64	90,497
1/23/2024	Sell	901	$0.67	$603.67	96,289
1/4/2024	Sell	310	$0.64	$198.40	97,190
11/17/2023	Sell	403	$1.63	$656.89	125,835
10/19/2023	Sell	358	$1.58	$565.64	126,595
10/3/2023	Sell	222	$1.98	$439.56	126,953
8/17/2023	Sell	1,653	$2.50	$4,132.50	127,175
7/19/2023	Sell	342	$3.56	$1,217.52	129,170
6/9/2023	Sell	5,045	$5.64	$28,453.80	129,512
4/19/2023	Sell	348	$3.71	$1,291.08	134,906
1/19/2023	Sell	1,557	$5.08	$7,909.56	74,342
11/10/2022	Sell	5,989	$8.00	$47,912.00	93,910
10/24/2022	Sell	2,000	$8.13	$16,260.00	99,899
10/21/2022	Sell	11,334	$8.45	$95,772.30	101,899
10/19/2022	Sell	345	$9.36	$3,229.20	113,233
4/20/2022	Sell	276	$6.68	$1,843.68	80,368
1/20/2022	Sell	1,563	$8.75	$13,676.25
2/22/2021	Sell	800	$43.14	$34,512.00	64,765
2/17/2021	Sell	2,320	$40.42	$93,774.40	68,926

Brett R. Hagen Buying and Selling Activity at AlloVir

AlloVir Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Today's Range

Now: $0.40

$0.40

$0.47

50 Day Range

MA: $0.66

$0.45

$1.01

2 Week Range

Now: $0.40

$0.40

$2.36

Volume

1,052,281 shs

Average Volume

595,584 shs

Market Capitalization

$46.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad